Concepedia
Statistics
Publications
26
Citations
2.2K
H-Index
21
Active since
1999
Affiliations
AstraZeneca (United Kingdom)(Current)
Shanghai Innovative Research Center of Traditional Chinese Medicine
Shanghai Jiao Tong University
Renji Hospital
The First Affiliated Hospital, Sun Yat-sen University
Paul R. Gavine is an author at AstraZeneca (United Kingdom) specializing in medicine, oncology, and molecular oncology.
Publications per year
1999–2023
AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
Paul R. Gavine, Lorraine Mooney, Elaine Kilgour et al. · Cancer Research · 2012 · 499 citations
Medicine, Oncology, Pharmacology +16
<i>FGFR2</i> Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
Liang Xie, Xinying Su, Lin Zhang et al. · Clinical Cancer Research · 2013 · 241 citations
FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study
Xin Su, Ping Zhan, Paul R. Gavine et al. · British Journal of Cancer · 2014 · 188 citations · Full text
Medicine, Oncology, Pathology +15
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically
Lucy C. Riches, Antonio G. Trinidad, Gareth Hughes et al. · Molecular Cancer Therapeutics · 2019 · 160 citations · Full text
Medicine, Oncology, Radiation Oncology +17
Translating the Therapeutic Potential of AZD4547 in <i>FGFR1</i> -Amplified Non–Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models
Jingchuan Zhang, Lin Zhang, Xinying Su et al. · Clinical Cancer Research · 2012 · 155 citations
Medicine, Oncology, Pharmacology +17
1–5 of 26